Sign in to view content

Number of Injections and Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER

Carl D. Regillo, MD

Video
Published 2020

Related

Interim Results and Key Learnings from an Ongoing Phase 2 Study of Encapsulated Cell Therapy Compared to Aflibercept in Patients With Wet AMD
Szilárd Kiss, MD
Annual Meeting Talks
2016
Treatment of CRVO: SCORE2 Sub-analysis
Michael S. Ip, MD
Updates from the Field
2019
Phase III Randomized Clinical Trial Comparing SB15 With Reference Aflibercept in Neovascular Age-Related Macular Degeneration 56-Week Results
Min Sagong, MD
Annual Meeting Talks
2023

Category: AMD-Neovascular

See more